Noven Gets Ready To Present Phentermine Report At AAPS Annual Meeting
In an announcement released by Noven Pharmaceuticals Inc (NASDAQ-NOVN), it is stated that the company scientists are on their way to deliver a presentation on four clinical transdermal research projects on 30 th October 2006 at the annual meeting of American Association of Pharmaceutical Scientists (AAPS).
The four transdermal research projects which are to be presented are “The Use of Acrylic PSA Concentration, Permeation Enhancement and Backing Material Selection to Control the Drug Delivery of a Benzothiazole in Transdermal Drug Delivery Systems,” “In-Vitro Transdermal Delivery of Phentermine,” “Transdermal Drug Delivery of Polar Derivatives of Ketoprofen Free Acid Through Human Cadaver Skin” and “The Effect of Primary and Secondary Packaging Materials on the Stability of Drug-In-Adhesive Transdermal Drug Delivery Systems.”
According to Juan Mantelle, Noven's Vice President and Chief Technical Officer, the Novan research and development team has been continuously attempting to make headway in the field of transdermal drug delivery and the report which is to be presented on 30 th October throws light on the company's efforts to make development on this arena and its dedication towards expanding the world of compounds that can be delivered transdermally.
The company's attempt to cover Phentermine in its reports regarding transdermal drug delivery will reveal another aspect of the medication Phentermine, which is in fact used as a short term treatment of obesity along with dieting and behavior modification therapy.
Source: genengnews.com October 30, 2006 |
